Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Genitourinary 1

Conditions

Urologic Neoplasms 1Urinary Bladder Neoplasms 1Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × INDUSTRY × apatorsen × Clear all
NCT01454089 2016-10-07

A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer

Achieve Life Sciences

Phase 2 Completed
183 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

NCT00487786 2016-01-18

Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer

Achieve Life Sciences

Phase 1 Completed
64 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡